FI872801A0 - Foerfarande foer anvaendning av bar1 foer avsoendring av fraemmande proteiner. - Google Patents

Foerfarande foer anvaendning av bar1 foer avsoendring av fraemmande proteiner.

Info

Publication number
FI872801A0
FI872801A0 FI872801A FI872801A FI872801A0 FI 872801 A0 FI872801 A0 FI 872801A0 FI 872801 A FI872801 A FI 872801A FI 872801 A FI872801 A FI 872801A FI 872801 A0 FI872801 A0 FI 872801A0
Authority
FI
Finland
Prior art keywords
foer
fraemmande
avsoendring
proteiner
bar1
Prior art date
Application number
FI872801A
Other languages
English (en)
Finnish (fi)
Other versions
FI872801A (fi
Inventor
Vivian L Mackay
Original Assignee
Vivian L Mackay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivian L Mackay filed Critical Vivian L Mackay
Publication of FI872801A publication Critical patent/FI872801A/fi
Publication of FI872801A0 publication Critical patent/FI872801A0/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/60Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
FI872801A 1985-10-25 1987-06-24 Foerfarande foer anvaendning av bar1 foer avsoendring av fraemmande proteiner. FI872801A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79130585A 1985-10-25 1985-10-25
PCT/US1986/002198 WO1987002670A1 (fr) 1985-10-25 1986-10-20 Procede d'utilisation de bar1 pour la secretion de proteines etrangeres

Publications (2)

Publication Number Publication Date
FI872801A FI872801A (fi) 1987-06-24
FI872801A0 true FI872801A0 (fi) 1987-06-24

Family

ID=25153298

Family Applications (1)

Application Number Title Priority Date Filing Date
FI872801A FI872801A0 (fi) 1985-10-25 1987-06-24 Foerfarande foer anvaendning av bar1 foer avsoendring av fraemmande proteiner.

Country Status (13)

Country Link
EP (1) EP0243465A1 (fr)
JP (1) JP2523562B2 (fr)
CN (1) CN1027179C (fr)
AU (2) AU6543286A (fr)
CA (1) CA1316133C (fr)
CZ (1) CZ284251B6 (fr)
DK (1) DK320287A (fr)
FI (1) FI872801A0 (fr)
HU (1) HU206897B (fr)
IE (1) IE63822B1 (fr)
SK (1) SK279041B6 (fr)
UA (1) UA41863C2 (fr)
WO (1) WO1987002670A1 (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK58285D0 (da) * 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
FI96121C (fi) * 1987-10-02 1996-05-10 Zymogenetics Inc DNA-rakenne ja menetelmä heterologisen proteiinin tuottamiseksi
US5206699A (en) * 1988-05-06 1993-04-27 Gersan Establishment Sensing a narrow frequency band of radiation and gemstones
WO1990001063A1 (fr) * 1988-07-23 1990-02-08 Delta Biotechnology Limited Nouvelles sequences conductrices secretoires
WO1991013971A1 (fr) * 1990-03-13 1991-09-19 Hawaii Biotechnology Group, Inc. SYSTEME D'EXPRESSION A $i(NEUROSPORA)
DK82893D0 (da) * 1993-07-08 1993-07-08 Novo Nordisk As Peptid
CN102080070B (zh) 1995-03-17 2016-01-20 诺沃奇梅兹有限公司 新的内切葡聚糖酶
EP1231218B1 (fr) 1996-03-01 2008-05-14 Novo Nordisk A/S Peptide coupe-faim, ses compositions et son utilisation
ATE435033T1 (de) 2000-01-10 2009-07-15 Maxygen Holdings Ltd G-csf konjugate
RU2278123C2 (ru) 2000-02-11 2006-06-20 Максиджен Холдингз Лтд. Молекулы, подобные фактору vii или viia
BR0207576A (pt) 2001-02-27 2004-04-27 Maxygen Aps Variante glicosilada de um polipeptìdeo de interferon beta precursor (ifnb), processos de aumentar a glicosilação in vivo de uma molécula de ifnb precursora, de produzir uma molécula de ifnb glicosilada, para preparar uma variante conjugada e de tratar um mamìfero com esclerose múltiplam composição farmacêutica, molécula de ifnb variante, sequência de nucleotìdeo, vetor de expressão, célula hospedeira de glicosilação conjugado, e, uso de um conjugado
AU2002249096B2 (en) 2001-03-22 2007-06-28 Novo Nordisk Health Care Ag Coagulation factor VII derivatives
US6534059B2 (en) 2001-06-05 2003-03-18 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
CA2461003A1 (fr) 2001-09-27 2003-04-03 Novo Nordisk Health Care Ag Polypeptides de facteur vii de coagulation humain
ATE547519T1 (de) 2003-09-09 2012-03-15 Novo Nordisk Healthcare Ag Gerinnungsfaktor-vii-polypeptide
US8034326B2 (en) 2005-04-18 2011-10-11 Novo Nordisk A/S IL-21 variants
ES2368500T3 (es) 2005-08-16 2011-11-17 Novo Nordisk A/S Método para producir polipéptidos de insulina maduros.
EP2316930A1 (fr) 2005-09-14 2011-05-04 Novo Nordisk Health Care AG Polypéptides humains du facteur de coagulation VII
EP1996186A4 (fr) 2006-03-06 2009-07-22 Humagene Inc Procede de preparation de la thrombine recombinante humaine et du fibrinogene
EP2069396B1 (fr) 2006-09-08 2015-10-21 Ambrx, Inc. Polypeptide plasmatique humain modifie ou squelettes de fc et leurs utilisations
JP5503968B2 (ja) 2006-09-27 2014-05-28 ノボ・ノルデイスク・エー/エス 成熟インスリンポリペプチドの作製方法
CA2685596A1 (fr) 2007-05-02 2008-11-13 Ambrx, Inc. Polypeptides d'interferon beta modifies et leurs utilisations
NZ603812A (en) 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
NZ591235A (en) 2008-07-23 2012-07-27 Ambrx Inc Modified bovine g-csf polypeptides comprising non natural amino acid and their uses treating infections such as mastitis
US8349325B2 (en) 2008-12-23 2013-01-08 Abbott Laboratories Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making
WO2010103038A1 (fr) 2009-03-11 2010-09-16 Novo Nordisk A/S Variants de l'interleukine 21 se liant de manière antagoniste au récepteur de l'il-21
KR102184713B1 (ko) 2009-07-17 2020-12-01 오메로스 코포레이션 보체 활성화의 억제제로서의 masp 이소형
ES2583259T3 (es) 2009-12-01 2016-09-20 Novo Nordisk A/S Nuevas liasas alfa-amidantes de peptidil alfa-hidroxiglicina
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
CN104017063A (zh) 2009-12-21 2014-09-03 Ambrx公司 经过修饰的猪促生长素多肽和其用途
JP6148013B2 (ja) 2010-03-05 2017-06-14 リグショスピタレト 補体活性化のキメラ抑制分子
US20110229921A1 (en) 2010-03-18 2011-09-22 Abbott Laboratories METHODS OF ASSAYING URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (uNGAL) IN THE PROGNOSIS OF CADAVERIC KIDNEY TRANSPLANT FUNCTION IN A PATIENT, INCLUDING A PATIENT DIAGNOSED WITH DELAYED GRAFT FUNCTION (DGF), A METHOD OF ASSAYING uNGAL IN THE ASSESSMENT OF RISK OF DGF IN A PATIENT DIAGNOSED WITH EARLY GRAFT FUNCTION (EGF), AND RELATED KITS
WO2011163558A1 (fr) 2010-06-25 2011-12-29 Abbott Laboratories Matériaux et procédés pour le dosage d'anticorps anti-virus de l'hépatite c (hvc)
MY162837A (en) 2010-08-17 2017-07-31 Ambrx Inc Modified relaxin polypeptides and their uses
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
US20120115244A1 (en) 2010-11-09 2012-05-10 Abbott Laboratories Materials and methods for immunoassay of pterins
CN105821078A (zh) 2010-12-09 2016-08-03 巴斯德研究所 用于获得高产量重组蛋白表达的基于mgmt的方法
CA2857998C (fr) 2011-12-09 2021-01-19 Institut Pasteur Immunoessai de depistage multiplex
US8993248B2 (en) 2011-12-31 2015-03-31 Abbott Laboratories Truncated human vitamin D binding protein and mutation and fusion thereof and related materials and methods of use
DK2812024T3 (en) 2012-02-09 2018-07-23 Var2 Pharmaceuticals Aps TARGET ORIENTATION OF CHONDROITIN-SULPHATE GLYCANES
US20150307865A1 (en) 2012-10-15 2015-10-29 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
JP2014128262A (ja) * 2012-11-27 2014-07-10 Kirin Brewery Co Ltd 接合能を持つ酵母細胞株のスクリーニング方法
WO2019213331A1 (fr) 2018-05-01 2019-11-07 Ambrx, Inc. Procédé d'optimisation de l'expression d'anticorps
CN112789504A (zh) 2018-07-13 2021-05-11 瓦克特诊断有限责任公司 使用重组疟疾蛋白var2csa分离胎儿来源的循环细胞
HRP20240016T1 (hr) 2018-09-11 2024-03-29 Ambrx, Inc. Konjugati polipeptida interleukina-2 i njihove uporabe
CN113366015A (zh) 2018-10-19 2021-09-07 Ambrx公司 白细胞介素-10多肽缀合物、其二聚体及其用途
BR112021015832A2 (pt) 2019-02-12 2022-01-18 Ambrx Inc Composições que contêm conjugados de anticorpo-agonista de tlr, métodos e usos dos mesmos
WO2021183832A1 (fr) 2020-03-11 2021-09-16 Ambrx, Inc. Conjugués polypeptidiques d'interleukine-2 et leurs procédés d'utilisation
WO2021211331A1 (fr) 2020-04-13 2021-10-21 Abbott Point Of Care Inc. Procédés, complexes et kits pour détecter ou déterminer une quantité d'un anticorps anti-ss-coronavirus dans un échantillon
WO2022031804A1 (fr) 2020-08-04 2022-02-10 Abbott Laboratories Méthodes et kits améliorés pour détecter une protéine sars-cov-2 dans un échantillon
AU2021327396A1 (en) 2020-08-20 2023-03-23 Ambrx, Inc. Antibody-TLR agonist conjugates, methods and uses thereof
EP4271998A1 (fr) 2020-12-30 2023-11-08 Abbott Laboratories Procédés pour déterminer un antigène sras-cov-2 et anticorps anti-sras-cov-2 dans un échantillon
AU2022249223A1 (en) 2021-04-03 2023-10-12 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof
CN115806889B (zh) * 2022-09-28 2024-06-11 山东大学 一种提高基因表达水平的酿酒酵母工程菌及其构建方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4546082A (en) * 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4613572A (en) * 1983-08-15 1986-09-23 Kansas State University Research Foundation Yeast BAR1 gene plasmid
DE3537176C2 (de) * 1984-10-18 1994-06-09 Zymogenetics Inc Gewebeplasminogenaktivator und Verfahren zu seiner Herstellung
JPS61247384A (ja) * 1984-10-18 1986-11-04 チモ−ジエネテイツクス インコ−ポレ−テツド 酵母中でプラスミノ−ゲン活性化因子を発現する方法

Also Published As

Publication number Publication date
UA41863C2 (uk) 2001-10-15
CN1027179C (zh) 1994-12-28
EP0243465A1 (fr) 1987-11-04
IE63822B1 (en) 1995-06-14
AU676132B2 (en) 1997-03-06
CZ284251B6 (cs) 1998-10-14
JPS63501614A (ja) 1988-06-23
CN86107554A (zh) 1987-08-26
FI872801A (fi) 1987-06-24
HUT43624A (en) 1987-11-30
AU6543286A (en) 1987-05-19
JP2523562B2 (ja) 1996-08-14
SK776486A3 (en) 1998-06-03
IE862804L (en) 1987-04-25
DK320287D0 (da) 1987-06-23
CZ776486A3 (en) 1996-09-11
WO1987002670A1 (fr) 1987-05-07
SK279041B6 (sk) 1998-06-03
AU7400391A (en) 1991-07-18
DK320287A (da) 1987-06-23
CA1316133C (fr) 1993-04-13
HU206897B (en) 1993-01-28

Similar Documents

Publication Publication Date Title
FI872801A0 (fi) Foerfarande foer anvaendning av bar1 foer avsoendring av fraemmande proteiner.
FI850004A0 (fi) Foerfarande foer identifiering av nukleinsyror.
FI850090A0 (fi) Foerfarande foer framstaellning av naturstensimitationer.
FI850605A0 (fi) Foerfarande foer framstaellning av formar.
FI850951A0 (fi) Foerfarande foer framstaellning av kisel.
FI860957A0 (fi) Foerfarande foer foersnabbande av fixeringen av kromathaltiga traeskyddssalter.
FI850208A0 (fi) Foerfarande foer styrning av alkaliska cellulosakok.
FI850686L (fi) Foerfarande foer framstaellning av en flygskaerm.
FI850864A0 (fi) Foerfarande foer framstaellning av ribonukleinsyra.
FI850683L (fi) Anordning foer korsmaetning av fordon.
FI850031A0 (fi) Foerfarande foer anaerob rengoering av avfallsvatten.
FI850001A0 (fi) Anordning foer maetning av haerdningsgrad av betong.
FI850399L (fi) Uppvaermbart verktyg foer upphettning av roerfoerbindningsstycken.
FI850660A0 (fi) Foerfarande foer framstaellning av 3-aryloxi-3-fenylpropylamin.
FI850421A0 (fi) Foerfarande foer framstaellning av eldfasta tegelprodukter.
FI850450A0 (fi) Foerfarande foer framstaellning av en soetsaksprodukt.
FI850574A0 (fi) Bladverkande aemneskomposition foer bekaempning av oertliknande ograes.
FI850461A0 (fi) Foerfarande foer bromsning av asynkronmotor.
FI850561A0 (fi) Foerfarande foer framstaellning av betong.
FI850876A0 (fi) Foerfarande foer emballering av pappersrullar.
FI850464A0 (fi) Additionsblandning foer foerbaettring av koeldbeteendet av raooljemedeldestillat.
FI850420A0 (fi) Foerfarande foer maetning av fjaerrvaermefoerbrukning.
FI850059A0 (fi) Foerfarande foer framstaellning av en hylsa.
FI850931A0 (fi) Foerfarande foer tillvaratagande av vattnets tillfrysningsvaerme.
FI850353L (fi) Aendspont foer kantstoed av betong.

Legal Events

Date Code Title Description
FD Application lapsed
FD Application lapsed

Owner name: ZYMOGENETICS, INC.